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AbstrACt
Antimicrobial development for children remains 
challenging due to multiple barriers to conducting 
randomised clinical trials (CTs). There is currently 
considerable heterogeneity in the design and conduct of 
paediatric antibiotic studies, hampering comparison and 
meta- analytic approaches. The board of the European 
networks for paediatric research at the European 
Medicines Agency (EMA), in collaboration with the 
Paediatric European Network for Treatments of AIDS—
Infectious Diseases network ( www. penta- id. org), recently 
developed a Working Group on paediatric antibiotic CT 
design, involving academic, regulatory and industry 
representatives. The evidence base for any specific criteria 
for the design and conduct of efficacy and safety antibiotic 
trials for children is very limited and will evolve over time 
as further studies are conducted. The suggestions being 
put forward here are based on the adult EMA guidance, 
adapted for neonates and children. In particular, this 
document provides suggested guidance on the general 
principles of harmonisation between regulatory and 
strategic trials, including (1) standardised key inclusion/
exclusion criteria and widely applicable outcome 
measures for specific clinical infectious syndromes (CIS) 
to be used in CTs on efficacy of antibiotic in children; 
(2) key components of safety that should be reported in 
paediatric antibiotic CTs; (3) standardised sample sizes 
for safety studies. Summarising views from a range of 
key stakeholders, specific criteria for the design and 
conduct of efficacy and safety antibiotic trials in specific 
CIS for children have been suggested. The recommended 
criteria are intended to be applicable to both regulatory 
and clinical investigator- led strategic trials and could be 
the basis for harmonisation in the design and conduct 
of CTs on antibiotics in children. The next step is further 
discussion internationally with investigators, paediatric CTs 
networks and regulators.
WhAt is the problem?
Antimicrobial resistance (AMR) is a rapidly 
emerging problem, causing morbidity and 
mortality especially in vulnerable popula-
tions. Mortality attributable to AMR may be 
associated with discordant therapy, which is 
particularly challenging in neonates and chil-
dren due to the limited number of approved 
effective antimicrobials, the inadequate pipe-
line for novel antibiotics and the long delays 
noted in many documents between the adult 
and paediatric licensing of novel antibi-
otics.1 2 There is no evidence that the signif-
icant delays in paediatric licensing of new 
antibiotics is improving. Antimicrobial devel-
opment for children remains challenging 
due to multiple barriers to conducting clin-
ical trials (CTs), with nearly half of paediatric 
medicines in Europe prescribed off- label, 
without evidence on the optimal dosage or 
safety data.3 The Clinical Trials Transforma-
tion Initiative, aiming to develop and drive 
adoption of practices that will increase the 
quality and efficiency of CTs, recently organ-
ised a Multi- Stakeholder Expert Meeting 
with the aim to identify and address barriers 
in conducting antibacterial CTs in neonates 
and children.2 We have previously reported 
on the marked heterogeneity in the design 
and conduct of paediatric antibiotic trials, 
with a lack of standardisation of the key inclu-
sion/exclusion criteria and endpoints for 
specific clinical infectious syndromes (CIS) 
hampering comparison between studies and 
meta- analytic approaches.4
Among the initiatives put in place to 
improve the efficiency and feasibility of paedi-
atric CTs was the publication of a Paediatric 
Addendum to the Guideline on the evaluation of 
medicinal products indicated for treatment of bacte-
rial infections5 by the Committee for Medicinal 
Products for Human Use and the Infectious 
Diseases Working Party at the European 
Medicines Agency (EMA). The purpose of 
this publication was to provide some general 
consideration on the paediatric clinical devel-
opment programmes required to support the 
authorisation of antibacterials for treatment 
of infectious diseases in children AND in the 
optimal design and conduct of clinical inves-
tigator- led strategic trials.6 The board of the 
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European networks for paediatric research at the EMA, in 
collaboration with the Paediatric European Network for 
Treatments of AIDS—Infectious Diseases network, there-
fore developed a Working Group (WG) on paediatric 
antibiotic CT design, involving academic, regulatory and 
industry representatives from both the USA and Europe. 
This group aimed to provide practical guidance on the 
design and conduct of neonatal and paediatric antibiotic 
CTs in order to improve international harmonisation in 
this important area. Currently, the EMA recommends the 
conduct of single- dose/multi- dose pharmacokinetic (PK) 
studies to support the approval of an antibacterial agent 
to treat infectious diseases in paediatric patients.5
The evidence base for any specific criteria for the design 
and conduct of efficacy and safety antibiotic trials for chil-
dren is very limited and will evolve over time as further 
studies are conducted. The suggestions being put forward 
here are based on the adult EMA guidance, adapted for 
neonates and children.6–8 In particular, this document 
provides suggested guidance on the general principles 
of harmonisation between regulatory and strategic trials, 
including:
1. Standardised key inclusion/exclusion criteria and 
widely applicable outcome measures for specific CIS 
to be used in CTs on efficacy of antibiotic in children.
2. Key components of safety that should be reported in 
paediatric antibiotic CTs.
3. Standardised sample sizes for safety studies.
GenerAl prinCiples
There are clear differences between regulatory trials 
being conducted to obtain a marketing authorisation for 
a new molecular entity and strategic trials usually spon-
sored by academic institutions. However, where possible, 
similar standards should apply across both types of studies. 
This distinction is becoming less wide as collaboration 
between clinical academic CT networks and pharma to 
drive efficiency increases, with both groups committed 
to the more rapid delivery of high quality trials.2 Recent 
data has noted that there has been in general inadequate 
reporting of safety in investigator- led paediatric antibiotic 
CTs and marked heterogeneity of the key trial elements, 
for example, inclusion/exclusion criteria and definition 
and timing of end points.3 4
There is increasing recognition that for the great 
majority of paediatric regulatory antibiotic trials, for 
well- established classes, both efficacy and safety can be 
bridged from adult studies. Single- dose PK studies are 
difficult to perform and there needs to be a clear focus 
on reducing barriers to recruitment. In our view, single- 
dose PK studies do not need to be conducted only in the 
CIS where there is an adult licence but will recruit more 
efficiently as an ‘all comers’ study where the child may be 
in hospital with any CIS. We can see no scientific ratio-
nale why the PK for the great majority of antibiotics (eg, 
a beta lactam/beta lactam inhibitor combination—BL/
BLI) will be different if the child is stable and completing 
a course of antibiotics for complicated urinary tract infec-
tion, or a complicated intra- abdominal infection. The 
child should be clinically stable, on either intravenous or 
oral antibiotics, being given for treatment or prophylaxis. 
If the antibiotic has very predictable linear PK and a well 
described safety profile, then the cohorts across all ages, 
including neonates, should be opened at the same time. 
Wherever possible, the neonatal single- dose PK cohort 
should be included in the same protocol as the older 
age cohorts, as separate protocols may lead to significant 
delays in determining the neonatal dose.
The scientific rationale for a multi- dose study needs to 
be determined on a case by case basis. As can be seen 
from the sample sizes given below, multi- dose studies of 
less than around 100 children for well- established classes 
of antibiotics will not be adequately powered to deter-
mine any new safety signal that is not entirely predictable 
from that drug class. Some antibiotics that, for example, 
require a loading dose calculated from the single- dose PK 
study, will need a multi- dose validation PK study. There 
may be a rationale for certain novel antibiotics to gain 
experience of routine clinical use from an open label, 
all comers, multi- dose treatment study, while recognising 
that the study is not required for PK and is not powered 
for either safety or efficacy. There does not appear to 
be any clear scientific rationale for the great majority of 
well- established classes of antibiotics for randomisation 
between the novel agent and a standard of care (SOC) 
arm. Even if SOC can be controlled to a limited number 
of regimens (which is often difficult in studies requiring 
multiple sites to achieve the recruitment targets), as seen 
from the sample sizes given below, the trial would need 
to be recruiting a very substantial number of children 
to detect any novel safety signal that was not entirely 
predictable from the drug class. It should be emphasised 
that these comments only apply to well- established drug 
classes (eg, BL/BLIs, aminoglycosides, etc).
The optimal study design for neonates is evolving and 
requires further international consensus. There is an 
urgent global unmet clinical need for novel antibacterial 
agents to treat neonates, both term and preterm, with 
multidrug resistant bacterial infection causing neonatal 
sepsis. Equally, not every new antibiotic under develop-
ment needs evaluation in neonates, where, for example, 
there are already other treatment options. For many new 
antibiotics single- dose PK studies would be all that would 
reasonably be required.
The next step would be a prioritisation of the novel 
antibiotics that are a high priority for multi- dose safety 
and efficacy trials in neonates. This could be based on 
the WHO Priority Pathogen List, focussing on the most 
critical pathogens, specifically those agents active against 
carbapenem resistant organisms.9 For these relatively few 
antibiotics, PK, safety and efficacy data are required in 
the indication of neonatal serious/severe bacterial infec-
tion (SBI, sepsis). Evaluation of penetration of the drug 
into the central nervous system for these antibiotics is also 
required. With the majority of neonatal sepsis caused by 
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multidrug resistant Gram- negative pathogens, much of 
which is healthcare- associated, there is no obvious scien-
tific basis to divide neonatal sepsis into early and late onset 
sepsis and the general term neonatal serious bacterial 
infection is the most suitable term (as used by the WHO). 
These studies will need to recruit babies across all stages 
of prematurity and postnatal age. Given the challenges 
of recruitment into such a population and the need for 
such trials to recruit globally, active consideration should 
be given for establishing close collaboration between 
Pharma, the WHO, global paediatric infectious diseases 
CTs networks and other major stakeholders, similar to the 
structures that were developed for paediatric HIV infec-
tion.10 Novel trial designs need to be urgently considered 
allowing the inclusion of multiple agents within proto-
cols, focussing on obtaining both regulatory and public 
health outcomes within single trials. We urgently recom-
mend the WHO to convene a consensus meeting focused 
specifically on neonatal sepsis to drive forward the global 
collaboration required.
The reporting of pharmacovigilance data on antibi-
otics in neonates and children is currently limited. At the 
moment, a standardised method of conducting antibi-
otic pharmacovigilance in children and neonates has not 
been developed, particularly for drugs that are used off- 
label. This is an increasingly important area for all medi-
cines as key regulatory trials have smaller sample sizes 
related to cost considerations. The establishment of a 
network of different stakeholders (academics, physicians, 
regulators and industry) involving centres in all regions 
across the world would allow the conduct of prospective 
cohort studies using electronic data records as part of 
post- marketing surveillance (as has already been set up 
with paediatric HIV registries). Such approach could 
potentially allow data to be collected and easily pooled 
out at a relatively low cost.11
suggested key clinical and laboratory components of 
inclusion/exclusion criteria and endpoints for Cis in paediatric 
antibiotic Cts
In the absence of any clearly accepted criteria, while 
recognising the very limited evidence base but given the 
wide variation seen in reported CTs, the WG has devel-
oped suggestions for paediatric inclusion/exclusion 
criteria and endpoints for the most common CIS.
Based on the results of a recently conducted systematic 
review,4 the most frequently reported CIS- specific clinical 
and laboratory criteria for the enrolment and evaluation 
of children in antibiotic CTs were collected. These criteria 
were then compared with the EMA Guideline on the evalu-
ation of medicinal products indicated for treatment of bacterial 
infections,6–8 revised according to the expert opinion of 
the WG members, and summarised in table 1. The WG 
decided to adapt the adult EMA criteria for children and 
neonates in all those CIS in which a similar pathophys-
iology and a similar spectrum of pathogens across the 
target age groups could be anticipated. This has been 
also the principle that has be adopted in the Paediatric 
Addendum for the extrapolation of efficacy against an 
infectious disease from adults to paediatric patients.5 This 
situation applies to the majority of infectious diseases that 
occur both in adults and in one or more paediatric age 
subgroups. However, there are some cases in which the 
pathophysiology and the spectrum of pathogens differ 
substantially between children/neonates and adults. As 
discussed above, for example, this is the case of neonatal 
sepsis (neonatal SBI). In this case, age- specific criteria 
have been adopted specifically designed for the neonatal 
age.
Key components of safety in paediatric antibiotic Cts
Proper reporting of safety data when publishing clin-
ical studies would increase translation of results into 
clinical practice.12 We have previously published a 
systematic review of safety data reported in CTs of anti-
bacterial agents in children and neonates to determine 
if age- specific adverse events (AEs) could be identified 
for different antibiotic classes.3 The quality of reporting 
AEs was suboptimal in the great majority of CTs, due to 
the lack of detailed definitions of expected/unexpected 
AEs (with respect to the AEs that have been reported 
in adults and/or the mechanism of action of the study 
drug), grading, reference for Coding System, and age 
stratification of the results. To improve the quality of 
safety reporting we recommend that there should be a 
specific section on safety in every paediatric antibiotic CT. 
To allow an appropriate comparison between CTs, studies 
should provide:
 ► Justification of the sample size for safety, and defini-
tion of the safety population in studies having safety 
as a primary endpoint.
 ► Definition for:
 – How harms- related information was collected 
(mode of data collection, timing, attribution 
methods, harms- related monitoring and stopping 
rules).13
 – Predefinition of each specific clinical/laboratory/
imaging addressed AE.
 – Grading (mild, moderate, severe).
 – Relationship with the study drug (expected vs 
unexpected).
 – Reference for Coding System (taking into account 
that most groups are now using the Division of 
AIDS grading system).14
 ► Overall (all age groups together) analysis presented 
first, followed by stratification of safety assessments 
and results by different age groups.
 ► Data on any modification to randomised treatment 
OR withdrawals because of AEs.
 ► All the denominators and all absolute risks per arms 
and per AE type, grade, seriousness and severity.
standardising sample sizes for paediatric antibiotic Cts
Data obtained from underpowered studies limits the 
implementation of the result itself, wastes resources, and 
undermines the ethics of patients’ involvement. However, 
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al
 u
rin
ar
y 
d
ip
st
ic
k 
te
st
 (l
eu
co
cy
te
 e
st
er
as
e 
>
1+
, o
r 
ni
tr
ite
 p
os
iti
ve
) O
R
 
►
U
rin
al
ys
is
 (≥
5 
w
hi
te
 c
el
l c
ou
nt
s 
p
er
 h
ig
h-
 p
ow
er
 fi
el
d
 in
 c
en
tr
ifu
ge
d
 u
rin
e 
or
 ≥
10
 w
hi
te
 
ce
ll 
co
un
ts
 p
er
 m
m
3  
in
 u
nc
en
tr
ifu
ge
d
 u
rin
e 
an
d
 b
ac
te
riu
ria
 w
ith
 a
ny
 b
ac
te
ria
 p
er
 h
ig
h-
 
p
ow
er
 fi
el
d
).
A
N
D  
►
A
t 
le
as
t 
tw
o 
of
 t
he
 fo
llo
w
in
g 
cl
in
ic
al
 o
r 
b
io
lo
gi
ca
l s
ig
ns
:
 –
Fe
ve
r 
w
ith
 t
em
p
er
at
ur
e 
of
 3
8°
C
 o
r 
hi
gh
er
.
 –
G
en
er
al
, n
on
-  s
p
ec
ifi
c 
si
gn
s 
(fo
r 
ch
ild
r e
n 
<
2 
ye
ar
s 
irr
ita
b
ili
ty
, v
om
iti
ng
, d
ia
rr
ho
ea
, 
fe
ed
in
g 
p
ro
b
le
m
s;
 fo
r 
ch
ild
re
n 
>
2 
ye
ar
s 
ab
d
om
in
al
 o
r 
fla
nk
 p
ai
n,
 u
rg
en
cy
, 
fr
eq
ue
nc
y,
 d
ys
ur
ia
, o
r 
su
p
ra
p
ub
ic
 t
en
d
er
ne
ss
).
 –
C
- r
ea
ct
iv
e 
p
ro
te
in
 o
r 
p
ro
ca
lc
ito
ni
n 
co
nc
en
tr
at
io
ns
 e
le
va
te
d
 a
cc
or
d
in
g 
to
 t
he
 lo
ca
l 
la
b
or
at
or
y.
A
N
D  
►
P
os
iti
ve
 u
rin
e 
cu
ltu
re
 r
es
ul
t 
w
ith
 n
o 
m
or
e 
th
an
 t
w
o 
sp
ec
ie
s 
of
 m
ic
ro
- o
rg
an
is
m
s 
O
R
 
►
S
p
on
ta
ne
ou
sl
y 
vo
id
ed
 u
rin
e 
w
ith
 ≥
10
5  
m
ic
ro
- o
rg
an
is
m
s 
p
er
 m
L 
of
 u
rin
e 
O
R
 
►
S
up
ra
p
ub
ic
 a
sp
ira
te
 o
r 
ur
in
ar
y 
ca
th
et
er
 w
ith
 ≥
10
4  
m
ic
ro
- o
rg
an
is
m
s 
p
er
 m
L 
of
 u
rin
e 
O
R
 
►
P
os
iti
ve
 b
lo
od
 c
ul
tu
re
 r
es
ul
t 
an
d
 n
o 
ot
he
r 
re
co
gn
is
ed
 c
au
se
.
 
►
C
hr
on
ic
/u
nd
er
ly
in
g 
co
nd
iti
on
s 
(e
g,
 k
no
w
n 
U
T 
ab
no
rm
al
iti
es
, 
m
al
ig
na
nc
y,
 im
m
un
od
efi
ci
en
cy
, 
sh
oc
k)
.
T
im
in
g
 f
o
r 
ev
al
ua
ti
o
n:
 
►
E
nd
 o
f t
re
at
m
en
t 
(E
O
T)
.
 
►
Te
st
 o
f c
ur
e 
(T
O
C
) 5
–7
 d
ay
s 
af
te
r 
th
e 
E
O
T.
 
►
Fo
llo
w
- u
p
 2
8 
d
ay
s 
af
te
r 
ra
nd
om
is
at
io
n.
Tr
ea
tm
en
t 
su
cc
es
s:
C
on
co
m
ita
nt
 c
lin
ic
al
 a
nd
 m
ic
ro
b
io
lo
gi
ca
l e
va
lu
at
io
n 
fo
r 
th
e 
TO
C
 
►
C
lin
ic
al
 c
ur
e 
d
efi
ne
d
 a
s 
d
ef
er
ve
sc
en
ce
.
 
►
M
ic
ro
b
io
lo
gi
ca
l c
ur
e 
d
efi
ne
d
 a
s 
ur
in
e 
st
er
ili
sa
tio
n.
S
us
p
ec
te
d
 o
r 
p
ro
ve
n 
ne
o
na
ta
l s
ev
er
e 
b
ac
te
ri
al
 in
fe
ct
io
n
In
cl
us
io
n 
cr
it
er
ia
20
E
xc
lu
si
o
n 
cr
it
er
ia
E
ffi
ca
cy
 e
nd
p
o
in
ts
A
t 
le
as
t 
tw
o 
cl
in
ic
al
 s
ym
p
to
m
s 
an
d
 a
t 
le
as
t 
tw
o 
la
b
or
at
or
y 
si
gn
s 
in
 p
re
se
nc
e 
of
 o
r 
as
 a
 
re
su
lt 
of
 s
us
p
ec
te
d
 o
r 
p
ro
ve
n 
in
fe
ct
io
n.
C
lin
ic
al
 c
ri
te
ri
a:
 
►
H
yp
er
th
er
m
ia
 o
r 
hy
p
ot
he
rm
ia
 a
nd
/o
r 
te
m
p
er
at
ur
e 
in
st
ab
ili
ty
.
 
►
R
ed
uc
ed
 u
rin
ar
y 
ou
tp
ut
 o
r 
hy
p
ot
en
si
on
 o
r 
m
ot
tle
d
 s
ki
n 
or
 im
p
ai
re
d
 p
er
ip
he
ra
l 
p
er
fu
si
on
.
 
►
A
p
no
ea
 o
r 
in
cr
ea
se
d
 o
xy
ge
n 
re
q
ui
re
m
en
t 
or
 r
eq
ui
re
m
en
t 
fo
r 
ve
nt
ila
tio
n 
su
p
p
or
t.
 
►
B
ra
d
yc
ar
d
ia
 s
p
el
ls
 o
r 
ta
ch
yc
ar
d
ia
 a
nd
/o
r 
rh
yt
hm
 in
st
ab
ili
ty
.
 
►
Fe
ed
in
g 
in
to
le
ra
nc
e 
or
 a
b
d
om
in
al
 d
is
te
ns
io
n.
 
►
Le
th
ar
gy
 o
r 
hy
p
ot
on
ia
 o
r 
irr
ita
b
ili
ty
.
 
►
S
ki
n 
an
d
 s
ub
cu
ta
ne
ou
s 
le
si
on
s,
 s
uc
h 
as
 p
et
ec
hi
al
 r
as
h.
La
b
o
ra
to
ry
 c
ri
te
ri
a:
 
►
W
B
C
 c
ou
nt
 <
40
00
 o
r 
>
20
 0
00
 c
el
ls
/m
m
3 .
 
►
P
la
te
le
t 
co
un
t 
<
10
0 
00
0/
m
m
3 .
 
►
C
R
P
 >
1.
5 
m
g/
d
L 
or
 p
ro
ca
lc
ito
ni
n 
≥2
 n
g/
m
L.
 
►
G
lu
co
se
 in
to
le
ra
nc
e 
as
 e
xp
re
ss
ed
 b
y 
b
lo
od
 g
lu
co
se
 v
al
ue
s 
>
18
0 
m
g/
d
L 
co
nfi
rm
ed
 a
t 
le
as
t 
tw
o 
tim
es
 o
r 
hy
p
og
ly
ca
em
ia
 <
40
 m
g/
d
L 
(2
.5
 m
m
ol
/L
).
 
►
A
ci
d
os
is
 a
s 
ch
ar
ac
te
ris
ed
 b
y 
b
as
e 
ex
ce
ss
 <
−
10
 m
m
ol
/L
 o
r 
la
ct
at
e 
w
ith
 v
al
ue
 a
b
ov
e 
2 
m
m
ol
/L
.
 
►
M
aj
or
 u
nd
er
ly
in
g 
co
nd
iti
on
s 
or
 
m
aj
or
 c
on
ge
ni
ta
l m
al
fo
rm
at
io
ns
.
 
►
D
ee
p
 s
ea
te
d
 lo
ca
lis
ed
 in
fe
ct
io
n 
(in
cl
ud
in
g 
os
te
om
ye
lit
is
, 
en
d
oc
ar
d
iti
s 
an
d
 m
en
in
gi
tis
).
T
im
in
g
 f
o
r 
ev
al
ua
ti
o
n:
 
►
E
nd
 o
f T
re
at
m
en
t 
(E
O
T)
.
 
►
Te
st
 o
f C
ur
e 
(T
O
C
) 7
–1
0 
d
ay
s 
af
te
r 
th
e 
E
O
T.
 
►
Lo
ng
- t
er
m
 fo
llo
w
- u
p
 2
8 
d
ay
s 
af
te
r 
ra
nd
om
is
at
io
n.
C
lin
ic
al
 c
ur
e:
 
►
R
es
ol
ut
io
n 
or
 s
ig
ni
fic
an
t 
im
p
ro
ve
m
en
t 
of
 t
he
 b
as
el
in
e 
cl
in
ic
al
 s
ig
ns
 a
nd
 s
ym
p
to
m
s 
of
 
in
fe
ct
io
n 
A
N
D
 m
ic
ro
b
io
lo
gi
ca
l e
ra
d
ic
at
io
n 
or
 p
re
su
m
ed
 e
ra
d
ic
at
io
n 
(in
 c
as
e 
of
 p
os
iti
ve
 
b
lo
od
 c
ul
tu
re
) A
N
D
 n
o 
ne
w
 s
ym
p
to
m
s 
su
gg
es
tiv
e 
to
 n
eo
na
ta
l s
ep
si
s.
O
R
Tr
ea
tm
en
t 
fa
ilu
re
, a
ny
 o
f 
th
e 
fo
llo
w
in
g
:
 
►
D
ea
th
 u
p
 t
o 
28
 d
ay
s 
p
os
t-
 ra
nd
om
is
at
io
n.
 
►
P
er
si
st
en
ce
 o
f s
ig
ns
 a
nd
 s
ym
p
to
m
s 
p
re
se
nt
 a
t 
th
e 
en
ro
lm
en
t.
 
►
C
lin
ic
al
 d
et
er
io
ra
tio
n:
 e
m
er
ge
nc
e 
of
 a
ny
 s
ig
n 
of
 c
rit
ic
al
 il
ln
es
s 
at
 a
ny
 t
im
e 
or
 r
e-
 
em
er
ge
nc
e 
of
 a
 s
ig
n 
of
 c
lin
ic
al
 s
ev
er
e 
in
fe
ct
io
n 
af
te
r 
in
iti
al
 d
is
ap
p
ea
ra
nc
e.
 
►
A
ny
 c
ha
ng
e,
 m
od
ifi
ca
tio
n,
 o
r 
d
is
co
nt
in
ua
tio
n 
of
 a
llo
ca
te
d
 A
B
 t
he
ra
p
y 
b
ec
au
se
 o
f 
d
et
er
io
ra
tio
n 
in
 p
at
ie
nt
's
 c
on
d
iti
on
, d
ev
el
op
m
en
t 
of
 s
er
io
us
 in
te
rc
ur
re
nt
 il
ln
es
s 
or
 
co
m
p
lic
at
io
ns
.
Ta
b
le
 1
 
C
on
tin
ue
d
C
on
tin
ue
d
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C
o
m
p
lic
at
ed
 in
tr
a-
 ab
d
o
m
in
al
 in
fe
ct
io
ns
 (c
IA
I) 
(in
cl
ud
in
g
 lo
ca
lis
ed
 in
fe
ct
io
ns
 (e
g
, b
ili
ar
y 
an
d
 n
o
n-
 b
ili
ar
y 
o
rg
an
- s
p
ec
ifi
c 
in
fe
ct
io
ns
, a
b
sc
es
se
s,
 p
o
st
su
rg
ic
al
 s
ec
o
nd
ar
y 
in
fe
ct
io
ns
) a
nd
 d
iff
us
e 
p
er
it
o
ni
ti
s.
 1
0%
 o
f 
p
at
ie
nt
s 
sh
o
ul
d
 h
av
e 
a 
d
ia
g
no
si
s 
o
th
er
 t
ha
n 
co
m
p
lic
at
ed
 a
p
p
en
d
ic
it
is
)
In
cl
us
io
n 
cr
it
er
ia
E
xc
lu
si
o
n 
cr
it
er
ia
E
ffi
ca
cy
 e
nd
p
o
in
ts
D
ia
g
no
si
s 
o
f 
cI
A
I e
st
ab
lis
he
d
 d
ur
in
g
 p
ro
ce
d
ur
es
 s
uc
h 
as
 la
p
ar
o
to
m
y,
 la
p
ar
o
sc
o
p
y 
o
r 
p
er
cu
ta
ne
o
us
 d
ra
in
ag
e
 
►
P
at
ie
nt
 h
as
 o
rg
an
is
m
s 
cu
ltu
re
d
 fr
om
 p
ur
ul
en
t 
m
at
er
ia
l f
ro
m
 in
tr
a-
 ab
d
om
in
al
 s
p
ac
e 
ob
ta
in
ed
 d
ur
in
g 
a 
su
rg
ic
al
 o
p
er
at
io
n 
fo
r 
th
e 
cu
rr
en
t 
in
fe
ct
io
n 
or
 n
ee
d
le
 a
sp
ira
tio
n 
O
R
 
►
O
rg
an
is
m
s 
cu
ltu
re
d
 fr
om
 d
ra
in
ag
e 
fr
om
 s
ur
gi
ca
lly
 p
la
ce
d
 d
ra
in
 (e
g,
 c
lo
se
d
 s
uc
tio
n 
d
ra
in
ag
e 
sy
st
em
, o
p
en
 d
ra
in
, T
- t
ub
e 
d
ra
in
) O
R
 
►
O
rg
an
is
m
s 
cu
ltu
re
d
 fr
om
 b
lo
od
 a
nd
 r
ad
io
gr
ap
hi
c 
ev
id
en
ce
 o
f i
nf
ec
tio
n 
(e
g,
 a
b
no
rm
al
 
fin
d
in
gs
 o
n 
ul
tr
as
ou
nd
, C
T 
sc
an
, M
R
I, 
or
 r
ad
io
la
b
el
 s
ca
ns
 (g
al
liu
m
, t
ec
hn
et
iu
m
, e
tc
) o
r 
on
 a
b
d
om
in
al
 X
-  r
ay
).
A
N
D  
►
A
t 
le
as
t 
tw
o 
of
 t
he
 fo
llo
w
in
g 
si
gn
s 
or
 s
ym
p
to
m
s 
w
ith
 n
o 
ot
he
r 
re
co
gn
is
ed
 c
au
se
:
 –
Fe
ve
r 
(>
38
.5
°C
).
 –
N
au
se
a.
 –
V o
m
iti
ng
.
 –
A
b
d
om
in
al
 p
ai
n.
 –
Ja
un
d
ic
e.
 
►
C
hr
on
ic
/u
nd
er
ly
in
g 
co
nd
iti
on
s 
af
fe
ct
in
g 
su
rg
ic
al
 d
ec
is
io
n 
m
ak
in
g 
or
 t
ha
t 
w
ou
ld
 li
m
it 
re
co
ve
ry
 (e
g,
 h
ae
m
op
hi
lia
, 
se
ve
re
 c
ar
d
ia
c 
or
 r
es
p
ira
to
ry
 
co
m
or
b
id
iti
es
).
T
im
in
g
 f
o
r 
ev
al
ua
ti
o
n:
 
►
E
nd
 o
f t
re
at
m
en
t 
(E
O
T)
.
 
►
Te
st
 o
f c
ur
e 
(T
O
C
) 7
–1
0 
d
ay
s 
af
te
r 
th
e 
E
O
T.
 
►
Lo
ng
- t
er
m
 fo
llo
w
- u
p
 2
8 
d
ay
s 
af
te
r 
ra
nd
om
is
at
io
n.
C
lin
ic
al
 c
ur
e:
 
►
C
le
ar
an
ce
 o
f i
nf
ec
tio
n 
w
ith
 r
es
ol
ut
io
n 
of
 t
he
 b
as
el
in
e 
si
gn
s 
an
d
 s
ym
p
to
m
s 
su
ch
 t
ha
t 
no
 
ad
d
iti
on
al
 a
nt
ib
ac
te
ria
l t
he
ra
p
y 
or
 s
ur
gi
ca
l o
r 
p
er
cu
ta
ne
ou
s 
in
te
rv
en
tio
n 
is
 r
eq
ui
re
d
 a
t 
E
O
T 
A
N
D
 e
ra
d
ic
at
io
n 
or
 p
re
su
m
ed
 e
ra
d
ic
at
io
n 
of
 m
ic
ro
-  o
r g
an
is
m
s.
O
R
Tr
ea
tm
en
t 
fa
ilu
re
:
 
►
A
ny
 c
ha
ng
e,
 m
od
ifi
ca
tio
n,
 o
r 
d
is
co
nt
in
ua
tio
n 
of
 a
llo
ca
te
d
 A
B
 t
he
ra
p
y 
b
ec
au
se
 o
f 
d
et
er
io
ra
tio
n 
in
 p
at
ie
nt
's
 c
on
d
iti
on
, d
ev
el
op
m
en
t 
of
 s
er
io
us
 in
te
rc
ur
re
nt
 il
ln
es
s 
or
 
co
m
p
lic
at
io
ns
 (e
g,
 a
b
sc
es
s,
 w
ou
nd
 in
fe
ct
io
n,
 p
ro
lo
ng
ed
 fe
ve
r 
>
3 
d
ay
s,
 p
ro
lo
ng
ed
 
b
ac
te
ra
em
ia
), 
ne
ed
 fo
r 
ad
d
iti
on
al
 a
nt
ib
io
tic
s,
 n
ee
d
 fo
r 
op
er
at
iv
e 
or
 p
er
cu
ta
ne
ou
s 
in
te
rv
en
tio
n.
A
cu
te
 b
ac
te
ri
al
 s
ki
n 
an
d
 s
ki
n 
st
ru
ct
ur
e 
in
fe
ct
io
ns
 (A
B
S
S
S
I) 
(in
cl
ud
in
g
 s
ur
g
ic
al
 w
o
un
d
 in
fe
ct
io
ns
, d
ee
p
 a
b
sc
es
se
s,
 c
el
lu
lit
is
 a
nd
 e
ry
si
p
el
as
)
In
cl
us
io
n 
cr
it
er
ia
E
xc
lu
si
o
n 
cr
it
er
ia
E
ffi
ca
cy
 e
nd
p
o
in
ts
 
►
D
ia
gn
os
is
 o
f A
B
S
S
S
I r
eq
ui
rin
g 
sy
st
em
ic
 a
nt
ib
io
tic
 t
re
at
m
en
t,
 w
ith
 a
t 
le
as
t 
on
e 
of
 t
he
 
fo
llo
w
in
g:
 –
D
ra
in
ag
e/
d
is
ch
ar
ge
.
 –
E
ry
th
em
a.
 –
Fl
uc
tu
an
ce
.
 –
H
ea
t/
lo
ca
lis
ed
 w
ar
m
th
.
 –
P
ai
n/
te
nd
er
ne
ss
 t
o 
p
al
p
at
io
n.
 –
S
w
el
lin
g/
in
d
ur
at
io
n.
A
N
D
 a
t 
le
as
t 
tw
o
 o
f 
th
e 
fo
llo
w
in
g
:
 
►
Fe
ve
r 
or
 h
yp
ot
he
rm
ia
.
 
►
Le
uc
oc
yt
os
is
 o
r 
le
uc
op
en
ia
 o
r 
a 
le
ft
 s
hi
ft
 o
f b
an
d
 n
eu
tr
op
hi
ls
.
 
►
Ta
ch
yc
ar
d
ia
 (9
8t
h 
p
er
ce
nt
ile
 fo
r 
ag
e)
.2
1
 
►
Ta
ch
yp
no
ea
 (2
 S
D
 o
f n
or
m
al
 fo
r 
ag
e)
.2
1
 
►
C
hr
on
ic
/u
nd
er
ly
in
g 
co
nd
iti
on
s 
th
at
 w
ou
ld
 li
m
it 
re
co
ve
ry
 (e
g,
 
ne
ut
ro
p
en
ia
, d
ia
b
et
es
, o
th
er
 
im
m
un
od
efi
ci
en
ci
es
).
 
►
P
at
ie
nt
s 
w
ith
 s
us
p
ec
te
d
 a
nd
/
or
 c
on
fir
m
ed
 o
st
eo
m
ye
lit
is
 o
r 
se
p
tic
 a
rt
hr
iti
s.
 
►
P
at
ie
nt
s 
w
ith
 m
ild
 in
fe
ct
io
ns
 
th
at
 d
o 
no
t 
ne
ed
 s
ys
te
m
ic
 
an
tib
io
tic
s.
T
im
in
g
 f
o
r 
ev
al
ua
ti
o
n:
 
►
E
nd
 o
f T
re
at
m
en
t 
(E
O
T)
.
 
►
Te
st
 o
f c
ur
e 
(T
O
C
) 7
–1
0 
d
ay
s 
af
te
r 
th
e 
E
O
T.
 
►
Lo
ng
- t
er
m
 fo
llo
w
- u
p
 (L
FU
) 2
8 
d
ay
s 
af
te
r 
ra
nd
om
is
at
io
n.
C
lin
ic
al
 c
ur
e:
 
►
R
es
ol
ut
io
n 
or
 s
ig
ni
fic
an
t 
im
p
ro
ve
m
en
t 
of
 t
he
 b
as
el
in
e 
cl
in
ic
al
 s
ig
ns
 a
nd
 s
ym
p
to
m
s 
of
 
in
fe
ct
io
n 
at
 E
O
T 
vi
si
t 
A
N
D
 
►
N
o 
ne
ed
 fo
r 
ad
d
iti
on
al
 a
nt
ib
io
tic
s.
O
R
Tr
ea
tm
en
t 
fa
ilu
re
:
 
►
P
er
si
st
en
ce
 o
r 
p
ro
gr
es
si
on
 o
f s
ig
ns
 a
nd
 s
ym
p
to
m
s 
or
 d
ev
el
op
m
en
t 
of
 n
ew
 le
si
on
s 
at
 a
 
d
iff
er
en
t 
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in the safety review, only two trials provided the justifica-
tion for the sample size specifically for the safety popula-
tion, including those designed with safety as the primary 
endpoint.
In an attempt to provide a standardised sample size to 
be used in single- arm interventional paediatric antibiotic 
CTs having safety as a primary endpoint, based on the 
rates of AEs per single drug class reported in the system-
atic review, the WG considered some key underpinning 
concepts. First, the rates of AEs and serious AEs (SAEs) 
in children are generally low, often lower than in adults, 
and usually predictable by class; AEs/SAEs specific to 
children occur extremely rarely, but are important to 
detect; and blinded (placebo- controlled) or unblinded 
comparative trials aim to estimate the difference between 
AE rates with the new antibiotic versus a comparator, 
with sample sizes typically large if designed to exclude 
differences outside a non- inferiority margin, or powered 
only to detect very large reductions in AEs which may not 
be realistic.
Given this, a reasonable approach would be to ensure 
sufficient children receive a novel antibiotic to enable 
(1) a high probability of determining that the overall 
AE/SAE rate is estimated reasonably precisely and (2) a 
reasonable probability of observing an AE which occurs 
in 1/20 children, or equivalently, that an observation of 
zero events has an upper 97.5% CI which lies below 5%. 
This could be done within a single- arm interventional 
trial with a standard proportion test (as, eg, in Flahault 
et al15). Given an expected proportion of children expe-
riencing one or more AEs, and a maximum acceptable 
value for this proportion, the sample sizes in table 2 
provide the 0.95, 0.90 and 0.80 probability that the upper 
95% CI around the proportion of children experiencing 
one or more AEs in the new trial is below the maximum 
acceptable value. An observation of no AEs of a particular 
kind out of N children has an upper 97.5% CI limit which 
is approximately 3/N (as a proportion).16 For example, 
for 0 events observed from 60 children, the approxima-
tion is 3/n=3/60=1/20=0.05 (compared with the actual 
exact upper limit, which is 0.06).
A further analysis then considered the potential class- 
specific sample sizes using data from the safety systematic 
review discussed above.3 In table 2, the third, fifth and 
seventh columns represent the sample size that would 
provide a >0.80, >0.90 and >0.95 probability, respectively, 
that the final 95% CI around the estimated percentage 
experiencing AEs in the new trial was no more than 10% 
higher than the average rate provided in the second 
column. The fourth, sixth and eighth columns provide 
the upper 97.5% confidence limit around an observation 
of zero AEs of a particular type from this number of chil-
dren (ie, the degree of certainty that an AE that was not 
observed in the trial genuinely had a low frequency).
These sample sizes are intended to inform investigators 
of the number of children to be enrolled to adequately 
power single- arm studies on these antibiotic classes having 
safety as a primary endpoint.
WhAt next?
The WG has discussed general principles for the design of 
studies and put forward practical suggestions on clinical 
inclusion/exclusion criteria for children for antibiotic 
trials, where none previously existed. We have also put 
forward suggestions on how to improve safety reporting.
The collaboration between clinical academic CT 
networks and pharma is improving. However, one of the 
barriers in conducting CTs in children is the complexity 
of the inclusion/exclusion criteria which can be a barrier 
to recruitment. The group therefore attempted to draft 
criteria for each CIS that would be as simple and inclu-
sive as possible, to try and encourage as wide an adoption 
by both clinicians and industry, relying on the fact that 
investigators are keen to use widely recognised criteria 
when available. In this process, the regulatory agency will 
have the responsibility for the approval of CTs designed 
for obtaining a marketing authorisation for a new molec-
ular entity; on the other side, the sponsor will have the 
responsibility to ensure that the protocol is designed to 
be as efficient as possible and reflects the relevant current 
guidance documents for that specific clinical infection.
Considering the limited data currently available on 
paediatric pharmacology, it is clear that robust evidence 
of efficacy and safety of different drugs in children 
can only be gained if CTs are properly conducted and 
reported. This issue was raised by Saint- Raymond et al17 
who suggested additional reporting requirements to 
the 2010 Consolidated Standards of Reporting Trials 
Statement specifically for trials in children. Data on 
neonates are even more limited. To improve the quality 
of reporting and strengthen research in this age group, 
an extension of the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) state-
ment for neonatal infection research has been published 
recently—STROBE- Neonatal Infection.18 This would 
help the process of harmonisation in data collection and 
reporting, therefore increasing translation of results into 
clinical practice.
In summary, this document is intended to be compli-
mentary to the draft EMA ‘Addendum to the guideline on 
the evaluation of medicinal products indicated for treat-
ment of bacterial infections to address paediatric- specific 
clinical data requirements’. The WG focused on those 
aspects not specifically addressed in the draft Addendum, 
gathering evidence from both published literature and 
experience from the networks and members involved. 
The next step is further discussion internationally with 
investigators, paediatric CTs networks and regulators, and 
to work towards a wider harmonisation of trial design and 
conduct.
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